Table 1:
Patient population and clinical and treatment characteristics
| Variable | Level | N (%) |
|---|---|---|
| Gender | Male | 202 (72%) |
| Female | 78 (28%) | |
| Stage | 0/1 | 42 (15%) |
| 2 | 35 (13%) | |
| 3 | 43 (15%) | |
| 4 | 160 (57%) | |
| Disease Site | Larynx | 49 (18%) |
| Oral Cavity | 139 (50%) | |
| Oropharynx | 83 (30%) | |
| Hypopharynx | 9 (3%) | |
| ACE Comorbidities Score, n=279 | none | 82 (29%) |
| mild | 126 (45%) | |
| moderate | 48 (17%) | |
| severe | 23 (8%) | |
| HPVstat, n=257 | negative | 168 (65%) |
| positive | 89 (35%) | |
| Drinker | never | 26 (9%) |
| current | 186 (66%) | |
| former (quit >12 months) | 68 (24%) | |
| Smoker (cigarettes) | never | 62 (22%) |
| current | 132 (47%) | |
| former (quit >12 months) | 86 (31%) | |
| Initial Treatment | Surgery | 164 (59%) |
| Radiation | 14 (5%) | |
| Chemotherapy | 5 (2%) | |
| Chemoradiation | 82 (29%) | |
| Palliaffigtion/no treatment | 15 (5%) |